AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33301153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen’s kappa
Number of subjects: 0
Study 34458718 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid-containing product (HCP)
Number of subjects: 20
Study 34458718 — intervention group
Group type: COMPARATOR
Intervention: Non-skin care (Control)
Number of subjects: 20
Study 35449996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir (S.L. group)
Number of subjects: 250
Study 35449996 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir/Hydroxychloroquine/Azithromycin (OCH group)
Number of subjects: 250
Study 33829225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subsidies on healthy products and taxes on unhealthy products in the nudging and price salience condition
Number of subjects: 318
Study 33829225 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 318
Study 35562520 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-related humor
Number of subjects: 94
Study 35562520 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-unrelated humor
Number of subjects: 94
Study 35562520 — intervention group
Group type: COMPARATOR
Intervention: Non-humorous regulation
Number of subjects: 94
Study 32722931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus Automated Perimetry (FAP)
Number of subjects: 60
Study 36495775 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV): tidal volume = 6 ml/kg of predicted body weight, PEEP = 10 cmH2O, recruitment maneuvers
Number of subjects: 60
Study 36495775 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (SV): tidal volume = 10 ml/kg of predicted body weight, PEEP = 5 cmH2O
Number of subjects: 60
Study 36495775 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV)
Number of subjects: 60
Study 36495775 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (SV)
Number of subjects: 60
Study 33712249 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Volume Extension (EVE) with 5mg intrathecal bupivacaine
Number of subjects: 84
Study 33712249 — intervention group
Group type: COMPARATOR
Intervention: No EVE with 5mg intrathecal bupivacaine
Number of subjects: 84
Study 33712249 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Volume Extension (EVE) with 8mg intrathecal bupivacaine
Number of subjects: 84
Study 33712249 — intervention group
Group type: COMPARATOR
Intervention: No EVE with 8mg intrathecal bupivacaine
Number of subjects: 84
Study 35631280 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+EPA supplementation
Number of subjects: 29
Study 35631280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high‐oleic safflower oil)
Number of subjects: 29
Study 35742365 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 (psychomotor intervention program)
Number of subjects: 48
Study 35742365 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 (combined program: psychomotor intervention + whole-body vibration)
Number of subjects: 48
Study 35742365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 33453747 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Adolescent Behavior Inventory
Number of subjects: 2142
Study 34958394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-Lex discs
Number of subjects: 20
Study 34958394 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite serum
Number of subjects: 20
Study 34958394 — intervention group
Group type: COMPARATOR
Intervention: carbide bur alone
Number of subjects: 20
Study 34958394 — intervention group
Group type: COMPARATOR
Intervention: combination of carbide burs and Sof-Lex discs
Number of subjects: 20
Study 32051007 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral switch therapy for low-risk Staphylococcus aureus infection
Number of subjects: 215
Study 32051007 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (not explicitly mentioned in the abstract)
Number of subjects: 215
Study 33938307 — intervention group
Group type: EXPERIMENTAL
Intervention: PGX-guided treatment
Number of subjects: 182
Study 33938307 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 182
Study 32941700 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic
Number of subjects: 0
Study 32941700 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker
Number of subjects: 0
Study 32941700 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 0
Study 97434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 548
Study 97434094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 35576956 — intervention group
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy (carboplatin and etoposide)
Number of subjects: 462
Study 35576956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and etoposide)
Number of subjects: 462
Study 35576956 — intervention group
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy
Number of subjects: 462
Study 35576956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 462
Study 33472641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium infusion
Number of subjects: 27
Study 33472641 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 27
Study 36001620 — intervention group
Group type: EXPERIMENTAL
Intervention: Application-supported pathway for the emergency department (ED) care for atraumatic abdominal pain patients.
Number of subjects: 2000
Study 34992516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (En% fat, carbohydrates, protein: 52.3, 39.2, 8.0)
Number of subjects: 18
Study 34992516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (En% fat, carbohydrates, protein: 9.6, 81.5, 8.6)
Number of subjects: 18
Study 34992516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (En% fat, carbohydrates, protein: 10.6, 51.5, 36.9)
Number of subjects: 18
Study 34992516 — intervention group
Group type: COMPARATOR
Intervention: Plasma measurements (control group for comparison)
Number of subjects: 18
Study 32985780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraslow full-power shock wave lithotripsy
Number of subjects: 101
Study 32985780 — intervention group
Group type: COMPARATOR
Intervention: Slow-rate, power-ramping shock wave lithotripsy
Number of subjects: 101
Study 33010371 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway device (SGA)
Number of subjects: 9296
Study 33010371 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 9296
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: RefineNet
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Net
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-Net
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: UNet3D
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: ResUNet3D
Number of subjects: 313
Study 35533205 — intervention group
Group type: EXPERIMENTAL
Intervention: RefineNetPlus3D
Number of subjects: 313
Study 32554291 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP intervention (community engagement, CHW provided mHealth-guided clinical assessment, initial treatment, and referral)
Number of subjects: 14783
Study 32554291 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP intervention with ≥8 contacts
Number of subjects: 14783
Study 32554291 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14783
Study 35731889 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of suvorexant
Number of subjects: 38
Study 35731889 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of suvorexant
Number of subjects: 38
Study 35731889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32207140 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy (MET) with 0.4 mg daily tamsulosin
Number of subjects: 0
Study 32207140 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 35829772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan gel + 0.1 mg/mL CaneCPI-5 (Cg + Cane)
Number of subjects: 16
Study 35829772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan gel + 12,300 ppm NaF (Cg + NaF)
Number of subjects: 16
Study 35829772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan gel (Cg)
Number of subjects: 16
Study 35829772 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Nt)
Number of subjects: 16
Study 34753906 — intervention group
Group type: EXPERIMENTAL
Intervention: MPG-peptide
Number of subjects: 0
Study 32196621 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (MI) treatment
Number of subjects: 86
Study 32196621 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 86
Study 35107029 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) - 5 sets of 10 repetitions at 75% of one-repetition maximum
Number of subjects: 39
Study 35107029 — intervention group
Group type: COMPARATOR
Intervention: Sham Control (seated rest)
Number of subjects: 39
Study 33753043 — intervention group
Group type: EXPERIMENTAL
Intervention: dd‐MVAC (dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 97
Study 33753043 — intervention group
Group type: COMPARATOR
Intervention: dd‐MVAC+Pmab (dd‐MVAC with panitumumab)
Number of subjects: 97
Study 33753043 — intervention group
Group type: COMPARATOR
Intervention: dd‐MVAC and dd‐MVAC+Pmab
Number of subjects: 97
Study 33753043 — intervention group
Group type: EXPERIMENTAL
Intervention: dd‐MVAC+Pmab
Number of subjects: 97
Study 36054143 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (800 mg/day for 4 days)
Number of subjects: 38
Study 33431282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 44
Study 33431282 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release (MR)
Number of subjects: 44
Study 33431282 — intervention group
Group type: COMPARATOR
Intervention: Sham Dry Needling (sham DN)
Number of subjects: 44
Study 32022890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention (five 90-minute sessions)
Number of subjects: 20
Study 35578103 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory art-based activity (2 hours weekly for 12 weeks)
Number of subjects: 228
Study 35578103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no art-based intervention)
Number of subjects: 228
Study 34753480 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg orally once daily
Number of subjects: 75
Study 34753480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 35762612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic retrorectus mesh reinforcement (MESH group)
Number of subjects: 120
Study 35762612 — intervention group
Group type: COMPARATOR
Intervention: Primary closure of midline laparotomy (NOMESH group)
Number of subjects: 120
Study 33399309 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line HIV therapy
Number of subjects: 355
Study 33399309 — intervention group
Group type: EXPERIMENTAL
Intervention: TB co-infection
Number of subjects: 355
Study 33399309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4+ T-cell count
Number of subjects: 355
Study 35573994 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily somatropin 0.05 mg/kg/day
Number of subjects: 481
Study 35573994 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 481
Study 34258380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT) with apixaban plus clopidogrel
Number of subjects: 400
Study 34258380 — intervention group
Group type: COMPARATOR
Intervention: Triple antithrombotic therapy (TAT) with vitamin-K-antagonist (VKA) plus clopidogrel and acetylsalicylic acid
Number of subjects: 400
Study 32007604 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 175
Study 32007604 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium (DVPX)
Number of subjects: 175
Study 32670199 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlida granules, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Number of subjects: 880
Study 32670199 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Number of subjects: 880
Study 34169656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting with PRP
Number of subjects: 18
Study 34169656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 18
Study 34169656 — intervention group
Group type: COMPARATOR
Intervention: Routine podiatry care
Number of subjects: 18
Study 34905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of primaquine (0.25 mg base/kg)
Number of subjects: 81
Study 34905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of primaquine (0.0625 to 0.5 mg base/kg)
Number of subjects: 81
Study 34905220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 34651260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 0.5 ml PRP 48 h before embryo transfer
Number of subjects: 393
Study 34651260 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 393
Study 34036409 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DryField® PH
Number of subjects: 50
Study 34036409 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 50
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management offered by 13% (n=3) of surgeons in all scenarios.
Number of subjects: 23
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management offered by 43% (n=10) of surgeons only in cases presenting with symptoms.
Number of subjects: 23
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable surgical approach indicated by 43% (n=10) of surgeons.
Number of subjects: 23
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: No surgery for incontinence indicated by 9% (n=2) of participants.
Number of subjects: 23
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surgery favored by 43% of participants for asymptomatic sacral LMM.
Number of subjects: 23
Study 32382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management preferred by 57% of participants for asymptomatic sacral LMM.
Number of subjects: 23
Study 35504639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral fracture fixation (cement augmentation±screw fixation) within 7 days of randomisation.
Number of subjects: 13
Study 35504639 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of analgesia, and regular input from the medical and therapy team.
Number of subjects: 13
Study 32216556 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive Technology (AT) awareness and need assessment
Number of subjects: 250
Study 32216556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile/sound-based ATs
Number of subjects: 250
Study 32216556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-based ATs
Number of subjects: 250
Study 35477489 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Home-Based Physical Activity Intervention
Number of subjects: 312
Study 35477489 — intervention group
Group type: COMPARATOR
Intervention: Educational Attention control group
Number of subjects: 312
Study 34542671 — intervention group
Group type: EXPERIMENTAL
Intervention: CE (cross-education): strength training of the non-operative limb
Number of subjects: 44
Study 34542671 — intervention group
Group type: COMPARATOR
Intervention: CON (control): sham exercise of upper limb stretching
Number of subjects: 44
Study 34920733 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 62
Study 34920733 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 62
Study 32854533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 87
Study 32854533 — intervention group
Group type: COMPARATOR
Intervention: Stress Management Therapy (SMT) for 12 weeks
Number of subjects: 87
Study 34776442 — intervention group
Group type: EXPERIMENTAL
Intervention: EMMA app with smart home prompting
Number of subjects: 32
Study 34776442 — intervention group
Group type: COMPARATOR
Intervention: EMMA app only
Number of subjects: 32
Study 33886693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-Family DSME
Number of subjects: 221
Study 33886693 — intervention group
Group type: COMPARATOR
Intervention: Standard DSME
Number of subjects: 221
Study 33367600 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniofacial morphology in UCLP group
Number of subjects: 429
Study 33871648 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 179 mg cutaneous patch
Number of subjects: 619
Study 36070664 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach and smartphone application (app) driven intervention
Number of subjects: 256
Study 36070664 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 256
Study 33714169 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture therapy for 2 hours combined with rehabilitation training
Number of subjects: 0
Study 33714169 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training alone
Number of subjects: 0
Study 35427190 — intervention group
Group type: EXPERIMENTAL
Intervention: TreoMel-HDT
Number of subjects: 109
Study 35427190 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study 33795189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded spurs associated with posterior build-ups (SBU)
Number of subjects: 49
Study 33795189 — intervention group
Group type: COMPARATOR
Intervention: Bonded spurs alone (S)
Number of subjects: 49
Study 35766991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one 30- to 45-minute psychosocial counseling session with a psychosexual counselor plus written educational materials
Number of subjects: 31
Study 35766991 — intervention group
Group type: COMPARATOR
Intervention: Written materials alone
Number of subjects: 31
Study 33370833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 210
Study 33370833 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 210
Study 33370833 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer cell activity
Number of subjects: 210
Study 32817142 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-ADAPT6 (500 μg)
Number of subjects: 29
Study 32817142 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-ADAPT6 (250 μg)
Number of subjects: 29
Study 32817142 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-ADAPT6 (1,000 μg)
Number of subjects: 29
Study 35834226 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (8 cycles: oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, infusional fluorouracil 2400 mg/m2 over 46 hours, every 2 weeks)
Number of subjects: 126
Study 35834226 — intervention group
Group type: COMPARATOR
Intervention: mFOLFIRINOX followed by hypofractionated radiotherapy (7 cycles of mFOLFIRINOX followed by 33-40 Gy in 5 fractions or 25 Gy in 5 fractions)
Number of subjects: 126
Study 32056811 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 189
Study 32056811 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 189
Study 35616245 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training (16-week program)
Number of subjects: 23
Study 35616245 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular soccer training)
Number of subjects: 23
Study 33440243 — intervention group
Group type: EXPERIMENTAL
Intervention: RC18 (a novel recombinant fusion protein targeting BLyS)
Number of subjects: 23
Study 33440243 — intervention group
Group type: EXPERIMENTAL
Intervention: RC18
Number of subjects: 23
Study 32146440 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT) for 8 weeks, 3 times a week
Number of subjects: 28
Study 32146440 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 28
Study 32146440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 36217555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP) treatment biweekly for five sessions
Number of subjects: 23
Study 36217555 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 23
Study 36217555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction ratings
Number of subjects: 23
Study 36217555 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment using VAS
Number of subjects: 23
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to T2D
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to insulin resistance
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to β‐cell dysfunction
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid atherosclerotic plaque
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional anisotropy (white matter disease marker)
Number of subjects: 0
Study 33495378 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of brain atrophy
Number of subjects: 0
Study 34044738 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise program performed twice per day for one month
Number of subjects: 90